TABLE 1 Baseline characteristics of participants TABLE 1 Baseline characteristics of participants TABLE 1 Baseline characteristics of participants TABLE 1 Baseline characteristics of participants TABLE 1 Baseline characteristics of participants
Study participants (N=69)
Study participants (N=69)
Non-participants (N=23), P-value3 Not approached (N=14), P-value3
Child variables Child variables Child variables Child variables
Male sex, N (%) Male sex, N (%) Male sex, N (%) 47 (68%) 47 (68%) 14 (61%), P=.52 8 (57%), P=.44
Age at assessment, mean years (SD) Age at assessment, mean years (SD) Age at assessment, mean years (SD) 11.6 (2.8) 11.6 (2.8) 11.1 (4.3), P=.76 9.9 (2.3), P=.08
Time since diagnosis, mean days (SD) Time since diagnosis, mean days (SD) Time since diagnosis, mean days (SD) 53 (28) 53 (28)
Body Mass Index, mean (SD) Body Mass Index, mean (SD) Body Mass Index, mean (SD) 18.7 (3.7) 18.7 (3.7)
Parental education level1 Parental education level1 Parental education level1
Low-Middle N (%) Low-Middle N (%) 33 (51%) 33 (51%)
High, N (%) High, N (%) 32 (49%) 32 (49%)
Medical variables Medical variables Medical variables Medical variables
Tumor type Tumor type Tumor type
Low grade glioma, N (%) Low grade glioma, N (%) 33 (48%) 33 (48%)
Germ cell tumor, N (%) Germ cell tumor, N (%) 10 (15%) 10 (15%)
Craniopharyngioma, N (%) Craniopharyngioma, N (%) 9 (13%) 9 (13%)
High grade glioma, N (%) High grade glioma, N (%) 6 (8%) 6 (8%)
Medulloblastoma, N (%) Medulloblastoma, N (%) 6 (8%) 6 (8%)
Ependymoma, N (%) Ependymoma, N (%) 2 (3%) 2 (3%)
Other, N (%)2 Other, N (%)2 3 (4%) 3 (4%)
Tumor location Tumor location Tumor location
Posterior fossa, N (%) Posterior fossa, N (%) 29 (42%) 29 (42%) 8 (35%), P=.54 6 (43%), P=.95
Supratentorial medial structures, N (%) Supratentorial medial structures, N (%) 26 (38%) 26 (38%) 5 (22%), P=.16 5 (36%), P=.89
Cerebral lobes, N (%) Cerebral lobes, N (%) 14 (20%) 14 (20%) 10 (44%), P=.03* 3 (21%), P=.92
Started treatment Started treatment Started treatment
Neurosurgery, N (%) Neurosurgery, N (%) 63 (91%) 63 (91%)
Started chemotherapy, N (%) Started chemotherapy, N (%) 12 (17%) 12 (17%)
Started radiotherapy, N (%) Started radiotherapy, N (%) 13 (19%) 13 (19%)
Proton therapy, N (%) 5 (7%) 5 (7%)
Photon therapy, N (%) 8 (12%) 8 (12%)
Obstructive hydrocephalus, N (%) Obstructive hydrocephalus, N (%) 33 (48%) 33 (48%)
Hormone deficiency, N (%) Hormone deficiency, N (%) 18 (26%) 18 (26%)
Epilepsy, N (%) Epilepsy, N (%) 9 (13%) 9 (13%)